Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enoxaparin sodium - Sanofi

Drug Profile

Enoxaparin sodium - Sanofi

Alternative Names: Clexane; Decipar; Enoxaparin; Klexane; Levenox; Lovenox; PK 10169; PRY 005; RP 54563; RPY 005

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmuka
  • Developer G.L. Pharma; Italfarmaco; Sanofi; Thrombosis Research Institute
  • Class Anti-ischaemics; Antithrombotics; Ischaemic heart disorder therapies; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Embolism; Myocardial infarction; Thromboembolism; Thrombosis; Unstable angina pectoris
  • Phase III COVID 2019 infections
  • Suspended Small cell lung cancer

Most Recent Events

  • 02 May 2022 Sanofi in collaboration with Thrombosis Research Institute terminates the phase IIIb ETHICS trial in COVID-2019 infection in United Kingdom, Australia, Belgium, South Africa and Germany (SC, Injection), due to lower event rate and requirement of larger sample size (EudraCT2020-003125-39) (NCT04492254)
  • 30 Oct 2020 Phase-III clinical trials in COVID-2019 infections (Early-stage disease) in United Kingdom (SC) in October 2020 (EudraCT2020-003125-39) (NCT04492254)
  • 27 Oct 2020 Phase-III clinical trials in COVID-2019 infections (Early-stage disease) in Belgium, Germany, South Africa, Australia (SC), after October 2020 (NCT04492254) (EudraCT2020-003125-39)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top